Adjunct to Chemotherapy

Is there a way to use another treatment in conjunction to chemotherapy? While it is often referred to as an adjunct to chemotherapy, it’s also known as adjunctive therapy as well.

The entire purpose of this type of assistance is to be able to be used together with the treatment of chemotherapy or to be used after chemotherapy treatment.

This can be done in different forms of studies of drugs on the body and sometimes in a variety of different surgeries as well.

While most people who are undergoing treatment for various cancers will be using chemotherapy as their main option for trying to beat and defeat the issue, there are several studies out there that show the potential benefits of challenging chemotherapy to restore platinum sensitivity in cells.

It’s also important to note that there will be different studies that can and will be done, depending on the type of cancer and chemotherapy that is happening. In the world of medicine and science, there is typically never a “one-size-fits-all” approach due to the fact that there are always many different types of illnesses and options to approach.

The study that is discussed below pertains to a specific type of treatment and a specific type of illness and only discusses the outcome of that one study. This isn’t necessarily the outcome for different types of cancers, which is important to be aware of.

What is the meaning of adjunct to treatment?

This type of study and research is done in other types of treatments, but it’s specifically used to see if there is a way to find something that can assist the main treatment option with a positive outcome.

What is the real-world benefit of adjunct chemotherapy?

The benefit of this type of challenge and study is to see if patients who have mUC (metastatic urothelial carcinoma) can have cells that have died be restored to platinum sensitivity.

Re-challenging chemotherapy or treatment with pembrolizumab is the basis of what this study is about. Does one yield better results than the other?

The Study

The study consisted of 236 patients, all treated with pembrolizumab. 45 of those patients did not experience any type of progressive disease at the follow-up and were excluded from the study due to this, and 86 patients who discontinued using pembrolizumab after they were diagnosed with progressive disease were excluded as well.

This left 105 patients that were identified and were able to be used to compare the outcomes between being treated with pembrolizumab (80 patients) and those who re-challenged chemotherapy (25 patients) after they were diagnosed with progressive disease.

The results showed that those who were treated with re-challenging chemotherapy had a much longer lifespan than those who were treated using the continuation of pembrolizumab.

The average lifespan of the re-challenging chemotherapy participants was 13.5 months, while the other was only 5.8 months.

While there is always room for more studies to be done, this study shows that re-challenging chemotherapy does offer benefits in patients who have metastatic urothelial carcinoma.

How we can help

Haelan 951

This can be used to help promote health during cancer treatment. The liquid allows for maximum absorption and contains all five superfoods as discovered in 1991 by the National Cancer Institute.

Get Haelean 951 here.